Loading organizations...
§ Private Profile · Bristol, Bristol, United Kingdom
Biotechnology company developing antigen-specific immunotherapies for autoimmune diseases and allergies, focused on restoring immune tolerance.
Based in Hasselt, Belgium, Apitope is a biotechnology company developing antigen-specific immunotherapies designed to restore immune tolerance for treating autoimmune diseases and allergies. The enterprise utilizes a proprietary platform to identify peptide-based therapies, known as apitopes, which target conditions such as multiple sclerosis, Graves' disease, and uveitis without broadly suppressing the patient's immune system. Prior to its acquisition, the organization raised over €30 million in total venture funding, including a €12 million Series C round backed by Vesalius Biocapital and the Wales Life Sciences Investment Fund. After regaining global development rights for its lead multiple sclerosis candidate from Merck Serono in 2018, the business was acquired by Hangzhou-based Worg Pharmaceuticals in 2021 to expand its clinical-stage pipeline. Apitope was originally founded in 2002 by David Wraith as a spin-out from the University of Bristol.
Apitope has raised $13.5M across 1 funding round.
Apitope has raised $13.5M in total across 1 funding round.
Apitope has raised $13.5M across 1 funding round. Most recently, it raised $13.5M Series B in September 2015.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Sep 29, 2015 | $13.5M Series B | Brenig Preest | LRM, PMV, Vesalius Biocapital, Wyvern | Announced |
Apitope has raised $13.5M in total across 1 funding round.
Apitope's investors include Brenig Preest, LRM, PMV, Vesalius Biocapital, Wyvern.